Get the Stockscreener App
0.2397
15.98%
-0.0456
After Hours:
.23
-0.0097
-4.05%
Cero Therapeutics Holdings Inc stock is traded at $0.2397, with a volume of 40.22M.
It is down -15.98% in the last 24 hours and up +180.02% over the past month.
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.
See More
Previous Close:
$0.2853
Open:
$0.27
24h Volume:
40.22M
Relative Volume:
0.66
Market Cap:
$37.08M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+22.30%
1M Performance:
+180.02%
6M Performance:
-78.21%
1Y Performance:
+0.00%
1-Day Range:
$0.22
$0.27
1-Week Range:
$0.1714
$0.4477
52-Week Range:
$0.0636
$10.95
Cero Therapeutics Holdings Inc Stock (CERO) Company Profile
Name
Cero Therapeutics Holdings Inc
Sector
Industry
Phone
650-407-2376
Address
201 HASKINS WAY, SOUTH SAN FRANCISCO
Compare CERO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| CERO | 0.2397 | 37.08M | 0 | 0 | 0 | 0.00 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Cero Therapeutics Holdings Inc Stock (CERO) Latest News
Selling Your CERo Therapeutics Holdings Inc (CERO) Stock? Here’s What You Need To Know - Stocks Register
FDA clears CERo's new AML drug for phase 1 trials - Investing.com
FDA clears CERo's new AML drug for phase 1 trials By Investing.com - Investing.com UK
CERo Therapeutics, Inc. Receives FDA Clearance of - GlobeNewswire
CERo Therapeutics Secures FDA Clearance for Novel AML Treatment Clinical Trial | CERO Stock News - StockTitan
Cero Therapeutics holdings sees $325,000 stock sale by YK Bioventures - Investing.com UK
U.S. Stock market most volatile stocks: Neuronetics(-47.27%), Heron Therapeutics(-20.15%) and LogicMark(+94.36%) in early trading - Business Upturn
United Therapeutics (UTHR) Stock Dips Amid Broader Biotech Indus - GuruFocus.com
CERo Therapeutics Holdings, Inc. (CERO): 173% Stock Surge Driven by Promising Preclinical Data for Lead Compound CER-1236 - BP Journal
Crude Oil Down 3%; Aramark Posts Upbeat Earnings - Benzinga
Nasdaq Moves Lower; Canaan Shares Surge - Benzinga
U.S. Stock market: Binah Capital Group(+105.01%) and CERo Therapeutics(+152.00%) see strong gains, RAPT Therapeutics(−44.12%) declines during mid day trading - Business Upturn
U.S. Stock market: RAPT Therapeutics drops 41% while CERo Therapeutics surges 136% in early trading - Business Upturn
Dow Jumps Over 400 Points; Monday.com Shares Fall After Q3 Results - Benzinga
CERo Therapeutics, Inc. Presents Preclinical Data - GlobeNewswire
CERo's Cancer Drug Shows Breakthrough: Kills Ovarian Cancer Without Toxicity in Key Study | CERO Stock News - StockTitan
CEROCERo Therapeutics Holdings, Inc. Latest Stock News & Market Updates - StockTitan
Cero Therapeutics faces NASDAQ delisting - Investing.com India
Cero Therapeutics faces NASDAQ delisting By Investing.com - Investing.com UK
Cero Therapeutics Faces NASDAQ Delisting Over Low Stock Price - Investing.com India
Cero Therapeutics Faces NASDAQ Delisting Over Low Stock Price By Investing.com - Investing.com UK
CERo Therapeutics updates on clinical hold and management changes - Investing.com India
CERo Therapeutics updates on clinical hold and management changes By Investing.com - Investing.com South Africa
CERo Therapeutics Holdings, Inc. Announces Submission of IND Clinical Hold Complete Response Letter - Marketscreener.com
CERo Therapeutics, Inc. Provides Corporate Update - The Bakersfield Californian
CERO’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Are Investors Inclined To Sell Their CERo Therapeutics Holdings Inc. (NASDAQ: CERO) Holdings? - Stocks Register
A closer look at CERO’s price-to-free cash flow ratio - US Post News
CERo Therapeutics Holdings Inc.’s Market Journey: Closing Strong at 0.10, Up 0.63 - The Dwinnex
Take off with CERo Therapeutics Holdings Inc. (CERO): Get ready for trading - SETE News
Cero Therapeutics announces financial update and board changes - Investing.com India
Cero Therapeutics announces financial update and board changes By Investing.com - Investing.com South Africa
An analyst sees good growth prospects for CERo Therapeutics Holdings Inc. (CERO) - SETE News
CERo Therapeutics Holdings Inc. Inc. (CERO) Price Performance: The Role of Volume and Liquidity - The InvestChronicle
CERo Therapeutics Holdings Inc. (CERO) deserves closer scrutiny - US Post News
Trading Day Review: CERo Therapeutics Holdings Inc. (CERO) Gains Momentum, Closing at 0.09 - The Dwinnex
CERo Therapeutics appoints new CFO and CDO - Investing.com India
CERo Therapeutics appoints new CFO and CDO By Investing.com - Investing.com Canada
CERo Therapeutics Enhances Leadership for Clinical Advancements - TipRanks
CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer - ForexTV.com
CERo Therapeutics Holdings, Inc. Appoints Kristen Pierce as Chief Development Officer - Marketscreener.com
A Look at CERo Therapeutics Holdings Inc. (CERO) Shares in the Recent Past Indicates Growth - SETE News
Market cap of CERo Therapeutics Holdings Inc. [CERO] reaches 4.79M – now what? - The DBT News
CERo Therapeutics Holdings Inc. (CERO)’s stock price range in the last year - US Post News
Financial Fitness Check: Examining CERo Therapeutics Holdings Inc. (CERO)’s Key Ratios - The Dwinnex
Cero Therapeutics cancels special stockholder meeting By Investing.com - Investing.com Australia
Cero Therapeutics cancels special stockholder meeting - Investing.com
CERo Therapeutics Hldgs (NASDAQ:CERO) Stock Quotes, Forecast and News Summary - Benzinga
CERo Therapeutics seeks FDA meeting, reshuffles leadershi By Investing.com - Investing.com Australia
CERo Therapeutics says CEO Atwood, CFO Carter to step down - MSN
CERo Therapeutics’ Strategic Moves Amidst Leadership Change - TipRanks
Cero Therapeutics Holdings Inc Stock (CERO) Financials Data
There is no financial data for Cero Therapeutics Holdings Inc (CERO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
3.66%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):